Reuters logo
BRIEF-Ortho Dermatologics submits NDA to U.S. FDA for psoriasis treatment IDP-118
2017年9月5日 / 下午1点33分 / 19 天前

BRIEF-Ortho Dermatologics submits NDA to U.S. FDA for psoriasis treatment IDP-118

Sept 5 (Reuters) - Valeant Pharmaceuticals International Inc

* Ortho dermatologics submits new drug application to the u.s. Food and drug administration for psoriasis treatment idp-118

* Valeant - in both studies IDP-118 met primary efficacy endpoint

* Valeant - ‍ortho dermatologics’ nda for idp-118​ also includes long-term safety study with patients followed for one year Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below